Mišo Krstičević1, Milka Jerić2, Svjetlana Došenović3,4, Antonia Jeličić Kadić4,5, Livia Puljak6. 1. Department of Orthopedics, University Hospital Split, Split, Croatia. 2. Department of Dermatovenerology, General Hospital Zadar, Zadar, Croatia. 3. Department of Anesthesiology and Intensive Care Medicine, University Hospital Split, Split, Croatia. 4. Laboratory for Pain Research, University of Split School of Medicine, Šoltanska 2, 21000, Split, Croatia. 5. Department of Pediatrics, University Hospital Split, Split, Croatia. 6. Laboratory for Pain Research, University of Split School of Medicine, Šoltanska 2, 21000, Split, Croatia. livia@mefst.hr.
Abstract
PURPOSE: To systematically analyse randomised controlled trials (RCTs) about efficacy and safety of proliferative injection therapy (prolotherapy) for treatment of osteoarthritis (OA). METHODS: CENTRAL, Embase and MEDLINE were searched. Two reviewers independently conducted screening and data extraction. RCTs were assessed with the Cochrane risk of bias tool. Type of treatment, study design, dosing, efficacy outcomes and safety outcomes were analysed. The protocol was registered in PROSPERO (CRD42016035258). RESULTS: Seven RCTs were included, with 393 participants aged 40-75 years and mean OA pain duration from three months to eight years. Follow-up was 12 weeks to 12 months. Studies analysed OA of the knee joint (n = 5), first carpometacarpal joint (n = 1) and finger joints (n = 1). Various types of prolotherapy were used; dextrose was the most commonly used irritant agent. All studies concluded that prolotherapy was effective treatment for OA. No serious adverse events were reported. The studies had considerable methodological limitations. DISCUSSION: Limited evidence from low-quality studies indicates a beneficial effect of prolotherapy for OA management. The number of participants in these studies was too small to provide reliable evidence. CONCLUSIONS: Current data from trials about prolotherapy for OA should be considered preliminary, and future high-quality trials on this topic are warranted.
PURPOSE: To systematically analyse randomised controlled trials (RCTs) about efficacy and safety of proliferative injection therapy (prolotherapy) for treatment of osteoarthritis (OA). METHODS: CENTRAL, Embase and MEDLINE were searched. Two reviewers independently conducted screening and data extraction. RCTs were assessed with the Cochrane risk of bias tool. Type of treatment, study design, dosing, efficacy outcomes and safety outcomes were analysed. The protocol was registered in PROSPERO (CRD42016035258). RESULTS: Seven RCTs were included, with 393 participants aged 40-75 years and mean OA pain duration from three months to eight years. Follow-up was 12 weeks to 12 months. Studies analysed OA of the knee joint (n = 5), first carpometacarpal joint (n = 1) and finger joints (n = 1). Various types of prolotherapy were used; dextrose was the most commonly used irritant agent. All studies concluded that prolotherapy was effective treatment for OA. No serious adverse events were reported. The studies had considerable methodological limitations. DISCUSSION: Limited evidence from low-quality studies indicates a beneficial effect of prolotherapy for OA management. The number of participants in these studies was too small to provide reliable evidence. CONCLUSIONS: Current data from trials about prolotherapy for OA should be considered preliminary, and future high-quality trials on this topic are warranted.
Authors: A Berenfeld; W D Bessing; U Bisplinghoff; G Bittner; H O Matthiesen; H Tilscher; S Ramm; L Ebeling; H Schmitz Journal: Fortschr Med Date: 1991-12-10
Authors: Marita Cross; Emma Smith; Damian Hoy; Sandra Nolte; Ilana Ackerman; Marlene Fransen; Lisa Bridgett; Sean Williams; Francis Guillemin; Catherine L Hill; Laura L Laslett; Graeme Jones; Flavia Cicuttini; Richard Osborne; Theo Vos; Rachelle Buchbinder; Anthony Woolf; Lyn March Journal: Ann Rheum Dis Date: 2014-02-19 Impact factor: 19.103
Authors: Magdalena Richter; Tomasz Trzeciak; Maciej Owecki; Andrzej Pucher; Jacek Kaczmarczyk Journal: Int Orthop Date: 2015-02-26 Impact factor: 3.075
Authors: David Rabago; Jeffrey J Patterson; Marlon Mundt; Richard Kijowski; Jessica Grettie; Neil A Segal; Aleksandra Zgierska Journal: Ann Fam Med Date: 2013 May-Jun Impact factor: 5.166
Authors: Michael J Yelland; Paul P Glasziou; Nikolai Bogduk; Philip J Schluter; Mary McKernon Journal: Spine (Phila Pa 1976) Date: 2004-01-01 Impact factor: 3.468
Authors: Ahmed Samir Barakat; Nour Muhamad Ibrahim; Osama Elghobashy; Ahmed Maher Sultan; Khaled F M Abdel-Kader Journal: Int Orthop Date: 2019-06-22 Impact factor: 3.075
Authors: Bernie Garrett; Timothy Caulfield; Blake Murdoch; Matt Brignall; Atul Kumar Kapur; Susan Murphy; Erin Nelson; Jillian Reardon; Mark Harrison; Jonathan Hislop; Barbara J Wilson-Keates; Joseph Anthony; Peter S Loewen; Richard M Musoke; Joan Braun Journal: Health Soc Care Community Date: 2021-05-26